CELL INTELLIGENCE · 肿瘤细胞治疗研究

骨肉瘤“冷转热”的概念蓝图：从肿瘤微环境分层假说到适应性治疗前景

A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.

骨肉瘤中的代谢-免疫串扰：机制与治疗机会

Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities.

经工程化改造携带衰老细胞清除药物的 NK 细胞来源细胞外囊泡清除化疗诱导的衰老骨肉瘤细胞

NK-Cell-Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy-Induced Senescent Osteosarcoma Cells.

肿瘤分泌的细胞外囊泡通过触发炎性间充质干细胞发育削弱治疗应答

Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development.

我们的观察结果确立了 iMSCs 是导致耐药性的主要因素，揭示了 EVs 是触发 iMSC 发展的因素，并强调了一种有前景的联合策略，以提高骨癌患者的治疗反应。

肿瘤来源外泌体与免疫细胞在骨肉瘤进展和靶向治疗中的作用

Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy.

以巨噬细胞为中心的骨肉瘤免疫治疗：机制、重极化及转化策略

Macrophage-centered immunotherapy for osteosarcoma: mechanisms, repolarization, and translational strategies.

间充质干细胞来源外泌体作为多柔比星纳米药物载体经 SDF1-CXCR4 轴靶向治疗骨肉瘤

Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.

我们的结果表明，MSC 来源的 Exo 可作为优良的纳米载体，用于在骨肉瘤中特异且高效地递送化疗药物 Dox，从而增强对骨肉瘤的毒性并降低心脏组织中的毒性。我们进一步证明，Exo 的靶向能力源于 MSC 来源外泌体通过 SDF1-CXCR4 轴对骨肉瘤细胞的趋化作用。

解码骨肉瘤免疫微环境：检查点、疫苗与 CAR-T 细胞的新见解

Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells.

外泌体在骨肿瘤中的治疗潜力：骨肉瘤、软骨肉瘤与尤因肉瘤

The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma.

骨髓间充质干细胞来源外泌体改善人细胞系与小鼠骨肉瘤模型中的抗癌药物递送

Bone marrow mesenchymal stem cell-derived exosomes improve cancer drug delivery in human cell lines and a mouse osteosarcoma model.

我们的研究表明，BMSC 来源的外泌体可有效靶向骨肉瘤。